Off-label use

Off-label use means prescribing an approved drug for a purpose, a patient group or a dose that is not on its FDA-approved labeling. FDA describes this as the unapproved use of an approved drug, and it is legal: once a drug is approved, a licensed clinician may prescribe it for a condition the label does not name if they judge it medically appropriate. FDA regulates approval and marketing, not the practice of medicine.

The category is far from fringe — off-label prescribing is routine across pediatrics, oncology and psychiatry. In this space the most common example is Ozempic or Mounjaro prescribed for weight loss in someone without type 2 diabetes. Both are labeled for diabetes; both contain the same molecule as a product that is labeled for weight.

What changes off-label is not legality but leverage. FDA notes that when a drug is used off-label, the agency has not evaluated the safety and effectiveness of that specific use, and manufacturers generally may not promote it. For patients, the practical consequences are insurance and liability: a prior authorization reviewed against diabetes criteria will fail if the diagnosis is obesity, and some plans exclude off-label use outright.

The confusion worth correcting is the belief that off-label means experimental or unsafe. It does not. A drug prescribed off-label went through the same approval process; what is missing is an FDA review of that particular indication. Sometimes the evidence for an off-label use is extensive, and sometimes it is thin — the label alone does not tell you which.

Ask your prescriber whether your prescription is on-label or off-label and why, whether an on-label alternative exists for your situation, and how the claim will be coded. That last question predicts your coverage outcome more reliably than anything else. Our off-label prescribing review and prior-auth letter generator go further.